



## PRIOR AUTHORIZATION POLICY

- POLICY:** Immunologicals – Dupixent Prior Authorization Policy
- Dupixent® (dupilumab subcutaneous injection – Regeneron/Sanofi-Aventis)

**REVIEW DATE:** 03/22/2023; selected revision 05/10/2023 and 02/14/2024

### INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## CIGNA NATIONAL FORMULARY COVERAGE:

### OVERVIEW

Dupixent, an interleukin-4 receptor alpha antagonist, is indicated for the following uses:<sup>1</sup>

- **Asthma**, as an add-on maintenance treatment in patients  $\geq 6$  years of age with moderate-to-severe disease with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.  
Limitation of Use: Dupixent is not indicated for the relief of acute bronchospasm or status asthmaticus.
- **Atopic dermatitis**, for the treatment of patients  $\geq 6$  months of age with moderate-to-severe disease not adequately controlled with topical prescription therapies or when those therapies are not advisable.
- **Chronic rhinosinusitis with nasal polyposis (CRSwNP)** [i.e., nasal polyps], as an add-on maintenance treatment in adults with inadequately controlled disease.
- **Eosinophilic esophagitis**, in patients  $\geq 1$  year of age who weigh  $\geq 15$  kg.
- **Prurigo nodularis**, in patients  $\geq 18$  years of age.

### Clinical Efficacy

Timing of efficacy assessments varied by indication across the numerous pivotal studies in which Dupixent demonstrated benefit. In the asthma trials, efficacy with Dupixent was assessed as early as 24 weeks.<sup>2-5</sup> In atopic dermatitis, the majority of studies evaluated the efficacy of Dupixent at 16 weeks.<sup>1,6-10</sup> The pivotal studies involving patients with CRSwNP evaluated the primary efficacy endpoints following 24 weeks of treatment.<sup>1,11-13</sup> Patients continued treatment with intranasal corticosteroids throughout the studies.

In Dupixent's eosinophilic esophagitis pivotal study, patients  $\geq 12$  years of age were required to have disease confirmed by baseline endoscopic biopsies with a demonstration of eosinophilic infiltration on central reading (peak cell count  $\geq 15$  eosinophils per high-powered field) that was unresponsive to an 8 week course of treatment with a high-dose proton pump inhibitor.<sup>14</sup> Patients with other causes of eosinophilic esophagitis, such as hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis, were excluded from the study. In the first portion of this study, efficacy, as measured by objective assessments (e.g., intraepithelial eosinophil count) and subjective assessments (e.g., dysphagia symptoms), was evaluated after 24 weeks (6 months) of Dupixent therapy. A very similarly designed pivotal study evaluated the efficacy of Dupixent for the treatment of eosinophilic esophagitis in patients 1 to 11 years of age.<sup>1</sup> Endoscopic biopsy evidence of eosinophilic infiltration despite treatment with a proton pump inhibitor was again required for study enrollment.

Two pivotal studies, PRIME and PRIME2, evaluated Dupixent's efficacy in the treatment of prurigo nodularis.<sup>15,16</sup> To enroll, patients were required to have  $\geq 20$  identifiable nodular lesions in total on both legs, and/or both arms, and/or trunk and to have failed a 2-week trial of a topical corticosteroid. Patients with prurigo nodularis secondary to medications or a medical condition such as neuropathy or psychiatric disease were excluded from the studies. The primary endpoint was evaluated at Week 24 in PRIME and initially at Week 12 and again at Week 24 in PRIME2.

## **Guidelines**

### *Asthma Guidelines*

The Global Initiative for Asthma Global Strategy for Asthma Management and Prevention (2022) proposes a stepwise approach to asthma treatment.<sup>17</sup> The majority of patients can be managed with an inhaled corticosteroid (ICS) with or without a long-acting beta<sub>2</sub>-agonist and/or an additional controller. Dupixent is listed as an option for add-on therapy in patients  $\geq 6$  years of age with severe eosinophilic/Type 2 asthma or for patients  $\geq 12$  years of age who require treatment with a maintenance oral corticosteroid. Higher blood eosinophil levels and higher fractional concentration of exhaled nitric oxide may predict a good asthma response to Dupixent.

According to the European Respiratory Society/American Thoracic Society guidelines (2014; updated in 2020), severe asthma is defined as asthma which requires treatment with a high-dose ICS in addition to a second controller medication (and/or systemic corticosteroids) to prevent it from becoming

uncontrolled, or asthma which remains uncontrolled despite this therapy.<sup>18,19</sup> Uncontrolled asthma is defined as asthma that worsens upon tapering of high-dose ICS or systemic corticosteroids or asthma that meets one of the following four criteria:

- 1) Poor symptom control: Asthma Control Questionnaire consistently  $\geq 1.5$  or Asthma Control Test  $< 20$ ; OR
- 2) Frequent severe exacerbations: two or more bursts of systemic corticosteroids in the previous year; OR
- 3) Serious exacerbations: at least one hospitalization, intensive care unit stay, or mechanical ventilation in the previous year; OR
- 4) Airflow limitation:  $FEV_1 < 80\%$  predicted after appropriate bronchodilator withholding.

### *Atopic Dermatitis Guidelines*

Guidelines for the care and management of atopic dermatitis (with topical therapies in adults [2022], with phototherapy and systemic agents [2014]) do not address Dupixent.<sup>10,21</sup> However, the guidelines note that topical therapies remain the cornerstone of treatment for atopic dermatitis due to their efficacy and generally favorable safety profiles. If patients fail topical therapy, use of systemic therapy may be considered. European guidelines on atopic eczema (2022) have been updated to address Dupixent.<sup>22</sup> Candidates for systemic treatment (i.e., Dupixent) are patients with severe, highly symptomatic disease, patients who have failed topical therapy, or patients who are unable to participate in normal daily life activities with their non-systemic treatment regimen.

### *Chronic Rhinosinusitis with Nasal Polyps Guidelines*

The Joint Task Force on Practice Parameters (JTFPP) published a focused guideline update for the medical management of CRSwNP (2023), which updated recommendations regarding intranasal corticosteroids and biologic therapies.<sup>33</sup> Intranasal corticosteroids are recommended for the treatment of CRSwNP. Use of biologics (e.g., Dupixent) is also recommended. However, in patients who derived a sufficient benefit from other therapies such as intranasal corticosteroids, surgery, or aspirin therapy after desensitization, biologics may not be preferred. Conversely, biologics may be preferred over other medical treatment options in patients who continue to have a high burden of disease despite receiving at least 4 weeks of treatment with an intranasal corticosteroid.

The diagnosis of CRSwNP was not addressed in this focused guideline update, but previous guidelines have noted that the presence of two or more signs and symptoms of chronic rhinosinusitis (e.g., rhinorrhea, postnasal drainage, anosmia, nasal congestion, facial pain, headache, fever, cough, and purulent discharge) that persist for an extended period of time makes the diagnosis chronic rhinosinusitis likely.<sup>24-27</sup> However, this requires confirmation of sinonasal inflammation, which can either be done via direct visualization or computed tomography (CT) scan. Oral corticosteroids and surgical intervention were not specifically addressed in this update, but prior guidelines recommend short courses of oral corticosteroid as needed and consideration of surgical removal as an adjunct to medical therapy in

patients with CRSwNP that is not responsive or is poorly responsive to medical therapy.<sup>24,25,27</sup>

### *Eosinophilic Esophagitis Guidelines*

Guidelines for the management of eosinophilic esophagitis from the American Gastroenterological Association and the Joint Task Force on Allergy-Immunology Practice Parameters (2020) have not been updated since the FDA approval of Dupixent for this indication.<sup>23</sup> In patients with symptomatic disease, use of a proton pump inhibitor is recommended over no treatment, as is treatment with topical corticosteroids. Guidelines recommend diet modifications, such as an elemental diet (amino-acid based formulas) or an elimination diet, over no treatment. However, it is noted that patients who put a higher value on avoiding the challenges of adherence to these diets and the prolonged process of dietary reintroduction may reasonably decline this treatment option.

### *Prurigo Nodularis Guidelines*

A United States Expert Panel Consensus provides a practical approach for the diagnosis and management of prurigo nodularis (2021).<sup>29</sup> The primary findings in patients with prurigo nodularis are the presence of firm, nodular lesions; pruritus lasting at least 6 weeks; and history or signs, or both, of repeated scratching, picking, or rubbing. Goals of treatment are to reduce pruritus, interrupt the itch-scratch cycle, and completely heal prurigo nodularis lesions.

## **POLICY STATEMENT**

Prior Authorization is recommended for prescription benefit coverage of Dupixent. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with Dupixent as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Dupixent to be prescribed by or in consultation with a physician who specializes in the condition being treated.

- **Dupixent® (dupilumab subcutaneous injection – Regeneron/Sanofi-Aventis)**

**is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

### **FDA-Approved Indications**

- 1. Asthma.** Approve for the duration noted if the patient meets one of the following (A or B):
  - A) Initial Therapy.** Approve for 6 months if the patient meets the following (i, ii, iii, iv, and v):
    - i.** Patient is  $\geq 6$  years of age; AND
    - ii.** Patient meets ONE of the following (a or b):

- a)** Patient has a blood eosinophil level  $\geq 150$  cells per microliter within the previous 6 weeks or within 6 weeks prior to treatment with Dupixent or another monoclonal antibody therapy that may lower blood eosinophil levels; OR  
Note: Examples of monoclonal antibody therapies that may lower blood eosinophil levels include Dupixent, Adbry (tralokinumab-ldrm subcutaneous injection), Cinqair (reslizumab intravenous infusion), Fasentra (benralizumab subcutaneous injection), Nucala (mepolizumab subcutaneous injection), Tezspire (tezepelumab subcutaneous injection), and Xolair (omalizumab subcutaneous injection).
- b)** Patient has oral (systemic) corticosteroid-dependent asthma according to the prescriber (e.g., the patient has received  $\geq 5$  mg oral prednisone or equivalent per day for  $\geq 6$  months); AND
- iii.** Patient has received at least 3 consecutive months of combination therapy with BOTH of the following (a and b):
  - a)** An inhaled corticosteroid; AND
  - b)** At least one additional asthma controller or asthma maintenance medication; AND  
Note: Examples of additional asthma controller or asthma maintenance medications are inhaled long-acting beta<sub>2</sub>-agonists, inhaled long-acting muscarinic antagonists, leukotriene receptor antagonists, and monoclonal antibody therapies for asthma (e.g., Cinqair, Fasentra, Nucala, Tezspire, and Xolair). Use of a combination inhaler containing both an inhaled corticosteroid and additional asthma controller/maintenance medication(s) would fulfill the requirement for both criteria a and b.
- iv.** Patient has asthma that is uncontrolled or was uncontrolled at baseline as defined by ONE of the following (a, b, c, d, or e):  
Note: "Baseline" is defined as prior to receiving Dupixent or another monoclonal antibody therapy for asthma. Examples of monoclonal antibody therapies for asthma include Dupixent, Cinqair, Fasentra, Nucala, Tezspire, and Xolair.
  - a)** Patient experienced two or more asthma exacerbations requiring treatment with systemic corticosteroids in the previous year; OR
  - b)** Patient experienced one or more asthma exacerbation(s) requiring a hospitalization, an emergency department visit, or an urgent care visit in the previous year; OR
  - c)** Patient has a forced expiratory volume in 1 second (FEV<sub>1</sub>)  $< 80\%$  predicted; OR
  - d)** Patient has an FEV<sub>1</sub>/forced vital capacity (FVC)  $< 0.80$ ; OR
  - e)** Patient has asthma that worsens upon tapering of oral (systemic) corticosteroid therapy; AND
- v.** The medication is prescribed by or in consultation with an allergist, immunologist, or pulmonologist.
- B) Patient is Currently Receiving Dupixent.** Approve for 1 year if the patient meets the following (i, ii, and iii):
  - i.** Patient has already received at least 6 months of therapy with Dupixent; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy with Dupixent should be considered under criterion 1A (Asthma, Initial Therapy).

ii. Patient continues to receive therapy with one inhaled corticosteroid or one inhaled corticosteroid-containing combination inhaler; AND

iii. Patient has responded to therapy as determined by the prescriber.

Note: Examples of a response to Dupixent therapy are decreased asthma exacerbations; decreased asthma symptoms; decreased hospitalizations, emergency department visits, or urgent care visits due to asthma; decreased requirement for oral corticosteroid therapy.

**2. Atopic Dermatitis.** Approve for the duration noted if the patient meets one of the following (A or B):

**A) Initial Therapy.** Approve for 4 months if the patient meets the following (i, ii, iii, and iv):

i. Patient is  $\geq$  6 months of age; AND

ii. Patient has atopic dermatitis involvement estimated to be  $\geq$  10% of the body surface area according to the prescriber; AND

iii. Patient meets ALL of the following (a, b, and c):

**a)** Patient has tried at least one medium-, medium-high, high-, and/or super-high-potency prescription topical corticosteroid; AND

**b)** This topical corticosteroid was applied daily for at least 28 consecutive days; AND

**c)** Inadequate efficacy was demonstrated with this topical corticosteroid therapy, according to the prescriber; AND

iv. The medication is prescribed by or in consultation with an allergist, immunologist, or dermatologist.

**B) Patient is Currently Receiving Dupixent.** Approve for 1 year if the patient meets the following (i and ii):

i. Patient has already received at least 4 months of therapy with Dupixent; AND

Note: A patient who has received < 4 months of therapy or who is restarting therapy with Dupixent should be considered under criterion 2A (Atopic Dermatitis, Initial Therapy).

ii. Patient has responded to therapy as determined by the prescriber.

Note: Examples of a response to Dupixent therapy are marked improvements in erythema, induration/papulation/edema, excoriations, and lichenification; reduced pruritus; decreased requirement for other topical or systemic therapies; reduced body surface area affected with atopic dermatitis; or other responses observed.

**3. Chronic Rhinosinusitis with Nasal Polyps.** Approve for the duration noted if the patient meets one of the following (A or B):

**A) Initial Therapy.** Approve for 6 months if the patient meets the following (i, ii, iii, iv, v, and vi):

i. Patient is  $\geq$  18 years of age; AND

ii. Patient has chronic rhinosinusitis with nasal polyps as evidenced by direct examination, endoscopy, or sinus computed tomography (CT) scan; AND

- iii. Patient has experienced two or more of the following symptoms for at least 6 months: nasal congestion, nasal obstruction, nasal discharge, and/or reduction/loss of smell; AND
- iv. Patient meets BOTH of the following (a and b):
  - a) Patient has received at least 4 weeks of therapy with an intranasal corticosteroid; AND
  - b) Patient will continue to receive therapy with an intranasal corticosteroid concomitantly with Dupixent; AND
- v. Patient meets ONE of the following (a, b, or c):
  - a) Patient has received at least one course of treatment with a systemic corticosteroid for 5 days or more within the previous 2 years; OR
  - b) Patient has a contraindication to systemic corticosteroid therapy; OR
  - c) Patient has had prior surgery for nasal polyps; AND
- vi. The medication is prescribed by or in consultation with an allergist, immunologist, or an otolaryngologist (ear, nose, and throat [ENT] physician specialist).

**B) Patient is Currently Receiving Dupixent.** Approve for 1 year if the patient meets the following (i, ii, and iii):

- i. Patient has already received at least 6 months of therapy with Dupixent; AND  
Note: A patient who has received < 6 months of therapy or who is restarting therapy with Dupixent should be considered under criterion 3A (Nasal Polyps, Initial Therapy).
- ii. Patient continues to receive therapy with an intranasal corticosteroid; AND
- iii. Patient has responded to therapy as determined by the prescriber.  
Note: Examples of a response to Dupixent therapy are reduced nasal polyp size, improved nasal congestion, reduced sinus opacification, decreased sinonasal symptoms, improved sense of smell.

**4. Eosinophilic Esophagitis.** Approve for the duration noted if the patient meets one of the following (A or B):

**A) Initial Therapy.** Approve for 6 months if the patient meets the following (i, ii, iii, iv, v, vi and vii):

- i. Patient is  $\geq$  1 year of age; AND
- ii. Patient weighs  $\geq$  15 kg; AND
- iii. Patient has a diagnosis of eosinophilic esophagitis as confirmed by an endoscopic biopsy demonstrating  $\geq$  15 intraepithelial eosinophils per high-power field; AND
- iv. Patient does not have a secondary cause of eosinophilic esophagitis; AND  
Note: Examples of secondary causes of eosinophilic esophagitis are hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, and food allergy.
- v. Patient has received at least 8 weeks of therapy with a proton pump inhibitor; AND
- vi. Patient meets ONE of the following (a or b):
  - a) Patient has tried dietary modifications to treat/manage eosinophilic esophagitis; OR





Note: A patient who has received < 6 months of therapy or who is restarting therapy with Dupixent should be considered under criterion 5A (Prurigo Nodularis, Initial Therapy).

- ii. Patient has experienced a beneficial clinical response, defined by ONE of the following (a, b, or c):
  - a) Reduced nodular lesion count; OR
  - b) Decreased pruritus; OR
  - c) Reduced nodular lesion size.

## CONDITIONS NOT COVERED

- **Dupixent® (dupilumab subcutaneous injection – Regeneron/Sanofi-Aventis)**

**is(are) considered experimental, investigational, or unproven for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):**

### **1. Concurrent Use of Dupixent with another Monoclonal Antibody Therapy.**

The efficacy and safety of Dupixent in combination with other monoclonal antibody therapies have not been established.

Note: Monoclonal antibody therapies are Adbry® (tralokinumab-ldrm subcutaneous injection), Cinqair® (reslizumab intravenous injection), Fasenna® (benralizumab SC injection), Nucala® (mepolizumab SC injection), Tezspire® (tezepelumab-ekko SC injection), or Xolair® (omalizumab SC injection).

### **2. Concurrent Use of Dupixent with Janus Kinase (JAK) Inhibitors (oral or topical).**

Use of JAK inhibitors are not recommended for use in combination with other JAK inhibitors, biologic immunomodulators (e.g., Dupixent), or with other immunosuppressants.<sup>30-32</sup>

Note: Examples of JAK inhibitors are Cibinqo® (abrocitinib tablets), Rinvoq® (upadacitinib tablets), and Opzelura™ (ruxolitinib cream).

- 3.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

## REFERENCES

1. Dupixent® subcutaneous injection [prescribing information]. Tarrytown, NY: Regeneron/Sanofi-Aventis; January 2024.
2. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. *N Engl J Med.* 2018;378(26):2486-2496.
3. Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet.* 2016;388(10039):31-44.
4. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. *N Engl J Med.* 2018;378(26):2475-2485.
5. Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in children with uncontrolled moderate-to-severe asthma. *N Engl J Med.* 2021;385(24):2230-2240.

6. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med*. 2016;375(24):2335-2348.
7. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. *Lancet*. 2017;389:2287-2303.
8. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. *JAMA Dermatol*. 2020;156(1):44-56.
9. Paller AS, Siegfried EC, Thaci D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. *J Am Acad Dermatol*. 2020;83(5):1282-1293.
10. Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2022;400:908-919.
11. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicenter, randomized, double-blind, placebo-controlled, parallel-group phase3 trials. *Lancet*. 2019;394(10209):1638-1650.
12. Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. *JAMA*. 2016;315(5):469-479.
13. Jonstam K, Swanson BN, Mannent L, et al. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. *Allergy*. 2019;74(4):743-752.
14. Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults with adolescents with eosinophilic esophagitis. *N Engl J Med*. 2022;387(25):2317-2330.
15. Yosipovich G, Mollanazar N, Stander S, et al. Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: results from a 2<sup>nd</sup> Phase III trial (LIBERTY-PN PRIME) [presentation]. Presented at: the European Academy of Dermatology and Venereology; Milan, Italy; September 7-10, 2022.
16. Yosipovich G, Mollanazar N, Stander S, et al. Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: results from a Phase III trial (LIBERTY-PN PRIME 2) [presentation]. Presented at: the 2022 Annual Meeting of the American Academy of Dermatology; Boston, MA; March 25-29, 2022.
17. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2022. Available at: <http://www.ginasthma.org>. Accessed on March 16, 2023.
18. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation, and treatment of severe asthma. *Eur Respir J*. 2014;43:343-373.
19. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society Guideline. *Eur Respir J*. 2020;55:1900588.
20. Sidbury R, et al. Guidelines of care for the management of atopic dermatitis Section 3. Management and treatment with phototherapy and systemic agents. *J Am Acad Dermatol*. 2014;71(2): 327-349.
21. Sidbury R, Alikhan A, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. *J Am Acad Dermatol*. 2023 Jan 11 [Epub ahead of print].
22. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. *Eur Acad Dermatol Venereol*. 2022;36(9):1409-1431.
23. Hirano I, Chan ES, Rank MA, et al. AGA Institute and Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. *Gastroenterology*. 2020;158(6):1776-1786.
24. Peters AT, Spector S, Hsu J, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. *Ann Allergy Asthma Immunol*. 2014:347-385.
25. Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis: an evidenced-based focused 2017 guideline update. *Ann Allergy Asthma Immunol*. 2017;119(6):489-511.
26. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. *Otolaryngol Head Neck Surg*. 2015;152(2S):S1-S39.
27. Joint Task Force on Practice Parameters: American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma, and Immunology. Rhinitis 2020: a practice parameter update. *J Allergy Clin Immunol*. 2020;146:721-767.

28. Bachert C, Han JK, Wagenmann, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. *J Allergy Clin Immunol*. 2021;147(1):29-36.
29. Elmariah S, Kim B, Berger T, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. *J Am Acad Dermatol*. 2021;84(3):747-760.
30. Cibinqo® tablets [prescribing information]. New York, NY: Pfizer; February 2023.
31. Rinvoq® tablets [prescribing information]. North Chicago, IL: AbbVie; April 2023.
32. Opzelura® cream [prescribing information]. Wilmington, DE: Incyte; January 2023.
33. Rank MA, Chu DK, Bognanni A, et al. Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. *J Allergy Clin Immunol*. 2023;151(2):386-398.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria change.	03/16/2022
Selected Revision	<p><b>Asthma:</b> Criteria for a blood eosinophil level <math>\geq</math> 150 cells per microliter within the previous 6 weeks or within 6 weeks prior to any anti-interleukin therapy or Xolair was changed to prior to any treatment with Dupixent or another monoclonal antibody therapy that may lower blood eosinophil levels. Throughout criteria, updated notes to include examples of monoclonal antibody therapies to include Tezspire™ (tezepelumab subcutaneous injection), Adbry™ (tralokinumab-ldrm subcutaneous injection), and Xolair® (omalizumab subcutaneous injection). Criteria requiring the patient to have experienced one or more asthma exacerbation(s) requiring a hospitalization, or an emergency department visit in the previous year, were updated to include an urgent care visit as well.</p> <p><b>Eosinophilic Esophagitis:</b> New approval criteria for this indication were added. Initial approval criteria include an age requirement, a weight requirement, a confirmation of diagnosis, ruling out secondary causes of eosinophilic esophagitis, a previous trial of a proton pump inhibitor, a previous trial of either dietary modifications or a physician evaluation that dietary modifications are not appropriate, and specialist involvement.</p> <p><b>Conditions Not Covered</b> : Criteria were updated to recommend against use of Dupixent with another monoclonal antibody therapy. Previously, criteria listed anti-interleukin monoclonal antibody therapies and Xolair separately. Eosinophilic esophagitis was removed as a Condition Not Recommended for Approval.</p>	06/01/2022
Selected Revision	<p><b>Atopic Dermatitis:</b> The age of approval was reduced from <math>\geq</math> 6 years of age to <math>\geq</math> 6 months of age. Criteria providing initial approval for patients with &lt; 10% body surface area involvement were removed.</p>	06/15/2022
Selected Revision	<p><b>Prurigo Nodularis:</b> New approval criteria for this indication were added. Initial approval criteria include an age requirement, a nodular lesion threshold, a minimum duration of pruritus, a requirement that prurigo nodularis not have a secondary cause or if there is a secondary cause that it be adequately managed, a trial of a topical corticosteroid, and specialist involvement.</p>	10/19/2022
Annual Revision	<p><b>Conditions Not Covered</b> : Criteria were updated to clarify that use of Dupixent with another monoclonal antibody therapy is specific to Cinqair, Fasenra, Nucala, Tezspire, Xolair, and Adbry.</p>	03/22/2023
Selected Revision	<p><b>Conditions Not Covered</b> : Criteria were added for "Concurrent Use of Dupixent with Janus Kinase Inhibitors (JAKis) [oral or topical]."</p>	05/10/2023

Selected Revision	<p><b>Chronic Rhinosinusitis with Nasal Polyps:</b> Approval condition updated from "Nasal Polyps" to "Chronic Rhinosinusitis with Nasal Polyps." Duration of the intranasal corticosteroid requirement was changed from 3 months to 4 weeks.</p> <p><b>Eosinophilic Esophagitis:</b> The age of approval was reduced from <math>\geq 12</math> years of age to <math>\geq 1</math> year of age. Additionally, the weight requirement was reduced from <math>\geq 40</math> kg to <math>\geq 15</math> kg.</p>	02/14/2024
-------------------	--	------------

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.